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E
ndocytic pathways in mammalian 
cells are too varied and complex to 
ever be fully understood by tradi-
tional cell biological methods, thinks 
Lucas Pelkmans. Instead, data-driven 
omics approaches and mathematical mod-
eling will be more effective in revealing how 
the endocytic system works as a whole.
Crucial to Pelkmans’ studies are 
mammalian viruses, which enter and infect 
cells via many different endocytic routes. 
Pelkmans fi   rst worked on virus entry 
as a graduate student in Ari Helenius’ 
laboratory at the Swiss Federal Institute 
of Technology (ETH) in Zurich. There, 
he discovered that the SV40 virus trig-
gers local rearrangements of the actin 
cytoskeleton at its sites of entry, passing 
through a novel organelle called the caveo-
some on its way to the ER (1, 2). As a 
postdoc with Marino Zerial in Dresden, 
Pelkmans revealed a new mechanism by 
which caveolin coat proteins sort cargo 
within endosomes (3) before he took a 
broader approach to the subject by per-
forming an RNAi screen to identify kinases 
involved in endocytosis (4). Combining 
the results of this screen with careful 
observations of caveolin 
coat dynamics at the cell 
surface, Pelkmans was 
able to study the specifi  c 
functions of kinases in the 
assembly and local recy-
cling of caveolae (5).
In 2005, Pelkmans 
returned to the ETH as an 
assistant professor in the 
Institute of Molecular Sys-
tems Biology. He has con-
tinued to perform quantita-
tive and global analyses of 
virus entry, looking for patterns in the data 
that can illuminate fundamental rules of en-
docytosis and virus infection. In a recent 
interview, Pelkmans explained this “top-
down” approach, and how it compares to 
Lavoisier’s experiments that laid the foun-
dations of modern chemistry (6).
ENTRY POINT
What do you think you’d be if you weren’t 
a scientist?
I love snowboarding and sailing, but I doubt 
I could ever make a living out of that! I 
would probably be a biology teacher; that’s 
something I’d like. I also launched a bio-
science company with Ari Helenius and Urs 
Greber, and the management aspects of 
that were appealing. In the past, I thought 
of becoming a medical doctor, though that’s 
still rather close to science of course.
When did your interest in science begin?
I grew up in the Netherlands in a small city 
called Nijmegen. I went to one of those 
typical  Dutch schools, called Gymnasia, 
which focus on training science students. So 
I was already inspired a lot, in physics, math-
ematics, and biology. One time, our regular 
biology teacher was on sick leave and was 
temporarily replaced by a molecular biol-
ogist from the University. The way he talked 
about biology was really exciting. My 
mother says that I came home after school 
and told her I wanted to be a scientist. That 
probably infl  uenced me to study biology at 
university, where I really got hooked.
Why do you use viruses to 
study endocytosis?
Mammalian viruses have 
coevolved with their host; 
mammalian cells have mul-
tiple endocytic pathways 
and viruses hijack them, 
often in very specifi  c ways. 
Once you know that a virus 
takes endocytic pathway A 
and another virus takes 
pathway B, you have two 
very good tools to specifi  -
cally study and compare the pathways.
Viruses are generally easy to grow and 
purify in large quantities, and it’s quite easy to 
make them fl  uorescent. So you can produce 
biologically active virus particles that infect 
cells via these pathways, and easily follow 
them with time-lapse imaging, especially 
with the powerful single molecule detection 
capabilities of modern light microscopes.
Also, viruses tend to amplify certain 
signals or stimulate certain activities to be-
come more pronounced than in a noninfected 
cell, making the signal or activity easier to 
pick up. This isn’t just true for endocytosis, 
but for molecular cell biology in general. 
If you think about the fi  rst studies of gene 
transcription or the early days of protein 
folding, protein production, and exocytosis, 
they also all started with viruses.
GOING GLOBAL
As a postdoc in Marino Zerial’s group, 
what made you start taking a more global 
approach to studying virus entry?
Omics-based approaches were basically 
missing from the fi  eld of virology, and from 
our understanding of how mammalian 
viruses enter cells. And that was because 
genetic tools weren’t easy to apply, certainly 
not in a high throughput fashion in mamma-
lian cells. That all changed with the advent of 
RNAi, and so, while in Marino’s laboratory, 
I did the fi  rst RNAi screens on virus entry.
My focus was defi  nitely on under-
standing the endocytic pathways them-
selves. But these experiments also launched 
a new era in virology—we’re now able to 
look at what we call the infectome: the part 
of a host cell’s genome that is important for 
infection by a pathogen, be it a virus or an 
intracellular bacterium. Many people are 
doing this now, and the screens are getting 
larger and more sophisticated. We’ll prob-
ably reach saturation at some point, but it’s 
an essential phase to map out all the host 
genes involved in entry and infection.
Pelkmans takes a systems biology approach to endocytosis 
and viral entry.
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That’s something you can only do 
with such an approach—I wouldn’t quite 
call it a systems biology approach, but it’s 
heading that way.
How do you deﬁ  ne systems biology?
In the truest sense of the term, I would say 
that you try to study a system’s properties: 
things that emerge from the interactions 
between components. Complex assemblies 
work together in ways we often don’t fully 
understand in order to make a system hap-
pen the way it does—be it membrane traf-
fi  cking, vesicle internalization, or whatever. 
We try to get a quantitative feeling for the 
system’s behavior, so that we can start to 
describe it formally, and perhaps we’ll 
even be able to predict what will happen to 
it if we induce a certain perturbation. It’s 
more than just omics, that’s clear. But omics 
is defi  nitely an important fi  rst step.
In one review you compared the impact of 
systems biology to the transition from 
alchemy to modern chemistry during the 
18th century. What did you mean?
That referred to the data-driven aspect of sys-
tems biology, what people call the top-down 
approach. I think most molecular cell biolo-
gists would ultimately aim to be bottom-up: 
to be able to describe everything by knowing 
all the molecules involved and all of their in-
teractions and dynamics. Perhaps in E. coli 
you might be able to get there; but for some-
thing as complex as a mammalian cell, I 
think it’s questionable whether we’ll ever be 
able to do that, certainly in the near future.
Why am I skeptical about bottom-up 
approaches based on our current knowledge? 
Because whenever you start to do new exper-
iments, be it an RNAi screen or a proteom-
ics analysis or a quantifi  cation of large cell 
populations or intracellular objects, you re-
alize that there’s this tremendous complexity 
that we just didn’t know about. And when 
you realize that these are just the fi  rst experi-
ments, the complexity becomes completely 
overwhelming. That doesn’t mean bottom-
up approaches are useless, they’re defi  nitely 
very important, but I like to think about 
systems biology from a top-down view.
That’s where this reference to Antoine 
Lavoisier came from, because, in a way, 
you can see him doing something similar. 
In his case he looked at chemicals and sub-
stances, started to weigh them and measure 
their volume and so on. From the patterns 
in that data, something like a systematic 
periodic table emerged. In our case, we can 
start to see nonrandom patterns in cellular 
activities, and we can then follow up and try 
to explain them molecularly. That’s where 
data-driven approaches to cell biology can 
reveal new aspects of cellular behavior that, 
in the short term, can be more productive 
than bottom-up approaches.
FINDING THE PATTERN
Interpreting these data involves a lot 
of mathematics and computer modeling. 
Is that something you’ve always been 
comfortable with?
My background is in bio-
chemistry and molecular cell 
biology; I didn’t have any 
training in data-driven mode-
ling. So I had to learn these 
methods by trying them out 
with laboratory members and 
colleagues at the ETH who 
are experts in statistics and 
mathematics. In my case, I’d 
say it took about three years 
to get a feeling for which 
methods are appropriate and 
which aren’t. That doesn’t mean you can do 
all the formal mathematics, but you can at 
least understand the concepts and what each 
of the methods can do.
It’s very important for biologists to 
realize that it’s easy to make big mistakes 
if one uses the wrong multivariate statistics 
methods. So it requires a nice interaction 
with mathematicians and statisticians be-
cause there’s a clear question from the biolo-
gy side, and they can really help you out. But 
sometimes they have to revise their statisti-
cal methods to address the question, so both 
sides end up improving their own science.
What are you working on at the moment?
During virus infections, which cells become 
infected by viruses is thought to be a more 
or less random process. But the truth—
and this came out of our RNAi screens—
is that these patterns are specifi  c for dif-
ferent viruses. You see very specifi  c pat-
terns of infection. But which cells can be 
infected, and why?
Perhaps the ability of a virus to infect a 
cell correlates with a specifi  c phenotypic state 
of the cell. For instance, if a virus hijacks 
an endocytic pathway that is regulated by 
mTOR signaling, you expect that pathway 
to be active in cells that are actively grow-
ing. So the phenotypic state of a cell affects 
its endocytic activity which, as a conse-
quence, determines whether 
the cell can be infected or 
not. We’ve tested this idea, 
and it turns out to be largely 
true: you can nicely cor-
relate infections with par-
ticular phenotypic states of 
cells. These are specifi  c for 
different viruses.
For some viruses, like 
SV40, we’re starting to ex-
plain how this is determined 
at the molecular level. Cer-
tain kinases increase the 
formation of lipid rafts and are more active 
in some cells than in others, allowing this 
virus to infect them. We’re studying infec-
tion patterns a lot at the moment: it touches 
on the fundamental concept of heteroge-
neity within cell populations.
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Favorite scenes from Pelkmans’ snowboarding and sailing excursions.
“There’s this 
tremendous 
complexity that 
we just didn’t 
know about…
it becomes 
completely 
overwhelming.”